Synamics Therapeutics is at the forefront of AI-driven drug discovery, specifically targeting cancer treatment and drug resistance. The company has developed a proprietary platform called Dynaptive, which utilizes advanced artificial intelligence to model and predict how cancer cells may develop resistance to treatments. By focusing on the design of compounds that can preemptively address these resistance mechanisms, Synamics aims to ensure the long-term effectiveness of cancer therapies, adapting to the evolving nature of tumors.

Recently, Synamics joined the NVIDIA Inception Program, which provides startups with access to cutting-edge technology and resources to accelerate their development. Through this partnership, Synamics will utilize tools such as BioNeMo, an AI-powered cloud service designed for drug discovery, to enhance its Dynaptive platform. This collaboration is expected to significantly advance Synamics' capabilities in creating adaptive drugs, ultimately aiming to revolutionize cancer treatment and bring innovative therapies to market more rapidly.

Denmark

At Synamics Therapeutics, our innovative strategy is not just about treating cancer—it's about staying one step ahead. The heart of our approach lies in our sophisticated AI-driven resistance modeling. This allows us to not only confront existing cancer mutations but also to proactively anticipate and target potential future mutations. By predicting these future resistance pathways, our AI model guides the design of our small molecules to effectively combat evolving cancer threats. This forward-thinking approach ensures the sustained efficacy of our therapies, significantly enhancing patient outcomes and leading the way in the evolution of precision oncology.

Synamics

Company Details